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Background: Graves’ disease (GD) and Graves’ ophthalmopathy (GO) are autoimmune disorders, which might be
influenced by genetic factors. Copy number variation (CNV) is an important source of genomic diversity in humans,
and influences disease susceptibility. This study investigated the association between CNV in the TSHR and TLR7
genes and the development of GD and GO in a Chinese population in Taiwan.
Methods: For this case-control study, sample from 196 healthy controls and 484 GD patients, including 203 patients
with GO were studied. CNV was detected by real-time polymerase chain reaction (PCR) using TaqMan™ probes and
the relative copy number (CN) was estimated by using the comparative Ct method.
Results: The differences in the distribution of TSHR CNV in healthy controls and GD patients were statistically
significant (p value = 0.01). However, the difference in the distribution of TSHR CNV in the control group and the GO
group was not statistically significant (p value = 0.06). For TLR7 CNV, the results were not significantly different when
we compared the distribution in healthy controls and GD patients and in healthy controls and GO patients
(p values for Fisher’s exact test were 0.13 and 0.09, respectively). However, a lower than normal CNV for TLR7
(CNV < 2 for female and CNV < 1 for male) was found to have a protective effect against the development of GD
(odds ratio (OR) = 0.24; 95% confidence interval (CI), 0.07-0.75) after adjusting for age and gender.
Conclusions: These results suggested that TSHR and TLR7 CNV might be associated with susceptibility to GD.
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Copy number variation (CNV) refers to is a genomic vari-
ation in the number of copies of a >1-kb DNA segment
compared to a reference genome. Gene copy number
(CN) differences due to deletions, duplications, and inser-
tions might contribute to variations in gene expression,
phenotypic variation, and gene dosage. Therefore, CNVs
might play an important role in not only evolution and
adaptation to different environments, but also in suscepti-
bility to and severity of disease [1,2]. Recently CNV has
been used as a genetic marker for inter-individual variation* Correspondence: d0704@www.cmuh.org.tw
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reproduction in any medium, provided the orto investigate human genomic diversity. For example, the
associations between CNV and diseases such as autism
[3,4], schizophrenia [5], cancer [6-8], and autoimmune dis-
orders [9-13] have been discussed in numerous studies.
Graves’ disease (GD) is an organ-specific autoimmune
disease caused by autoantibodies against thyroid-stimulating
hormone receptors (TSHRs); these antibodies constitu-
tively stimulate the production of thyroid hormones. TSHR
is a 7-transmembrane domain G protein-coupled receptor
in the thyroid gland that binds thyroid-stimulating hor-
mone (TSH). Therefore, the TSHR gene on chromosome
14q is a candidate disease-susceptibility gene for GD and
the association between TSHR gene polymorphism and
GD has been investigated [14-16].
Graves’ ophthalmopathy (GO) is the most common
extrathyroidal manifestation of GD and affects 25–50%. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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flammatory disorder that affects the extraocular muscles
and the fatty and connective tissues in the orbit of the eye.
Studies have shown that genes related to the immune sys-
tem, such as human leucocyte antigen (HLA), cytotoxic
T cell antigen-4 genes (CTLA), CD103 and Interleukin13
(IL-13) are involved in the pathogenesis of GD or GO
[17,21,22]. Recently, toll-like receptors (TLRs), which play
important roles in eliciting human innate/adaptive im-
mune responses and developing chronic inflammation
[23], have become a new focus of basic immunological
investigation and might be associated with autoimmune
thyroiditis [24]. TLR7 gene, which is located on the X
chromosome, is expressed in human plasmacytoid den-
dritic cells (pDCs) and specifically recognizes single-
stranded RNA derived from viruses or immune complexes
associated with self-RNA. This results in the activation of
the pDCs and induces the secretion of large amounts of
interferon alpha (IFN-α), which in turn has a pivotal role
in the pathogenesis of GD/GO. Therefore, TLR7 gene
could be a potential immune-related disease-susceptibility
gene for GD/GO. In this study, we examined the associ-
ation of the CNV in TSHR and TLR-7 with susceptibility




The participants in this study were 196 healthy controls
and 484 GD patients which including 203 of them with
ophthalmopathy (GO) recruited from China Medical
University Hospital in Taiwan. All GD patients were exam-
ined by experienced endocrinologist and identified using
following criteria: having hyperthyroidism, having diffused
goiter and presence at least one of following observations:
positive results for thyroid-stimulating hormone (TSH) re-
ceptor receptor antibody test, diffusely increased 131I (iod-
ine-131) uptake in the thyroid gland, and exophthalmos.
GD patients were categorized according the NOSPECS
system recommended by the American Thyroid Associ-
ation [25]. The GD patients had proptosis with or with-
out more severe form (class 3-6) was defined as GO
(yes/no). The degree of proptosis was measured using an
exophthalmometer and was defined as the apex of the cor-
nea and the lateral orbital rim is more than 18 mm in ei-
ther eye or a 2-mm difference in the degree of protrusion
between the 2 eyes. The information regarding age, sex,
history of tobacco use, thyroid gland pathology and af-
fected anatomic sites were obtained from the question-
naire and blood samples were collected by venipuncture
for genomic DNA isolation. Informed consent was ob-
tained from each participant prior to inclusion in this
study and the human ethics committee of China Medical
University Hospital gave its approval for the study.DNA preparation and TaqMan real-time polymerase chain
reaction (rt-PCR)
The genomic DNA was extracted from peripheral blood
leukocytes of participants using the Genomic DNA kit
(Qiagen) according to the manufacturer’s instructions. It is
important to verify the quality of each genomic DNA in
order to get accurate CN. Therefore, all genomic DNA
were electrophoresed on an agaroes gel and integrity
scored from 1 to 4 (most degraded). Samples with scores
of 3 and 4 were discarded from analysis. Also, in order to
minimized DNA degradation, the template DNA were
freshly diluted from 200 μg/ml stock and used within 2
weeks.
Measurement of CN
The relative CN of the TSHR and TLR7 gene in each indi-
vidual was estimated using TaqMan real-time quantitative
polymerase chain reaction (rt-PCR) method that is suited
to large-scale genotyping. rt-PCR was performed using the
ABI 7900 HT sequence detection system. Amplification
reactions (14 μl) were carried out in duplicate with of tem-
plate DNA (10 ng), reference DNA (RNase P H1 RNA
gene (10 ng)), TaqMan Universal Master Mix buffer
(Applied Biosystems, Foster City, CA), 300 nM of each
primer and 200 nM of each fluorogenic probe (probe with
FAMTM dye and VIC® dye). Thermal cycling was initiated
with a first denaturation step of 10 min at 95°C, and
followed by 40 cycles of 15 sec at 95°C and of 1 min at
60°C. The relative gene CN for each individual was esti-
mated using the comparative Ct method (2–ΔΔCt method)
[26]. Briefly, this method calculates the difference in cycle
thresholds (ΔCt) (the number of PCR cycles required to
produce a set of fixed thresholds) between the gene of
interest and a reference gene (ribonuclease P, (RNase P).
Subsequent calculations normalize the ΔCt of each sample
to a calibrator that is assigned a relative expression value of
1.00 (ΔCt). Assuming that the amount of PCR product
doubles with each successive PCR cycle, calculating the
2–ΔΔCt value will provide the relative amount of DNA ini-
tially available for amplification in each quantitative PCR
run. Therefore, the 2–ΔΔCt method reveals differences in
the relative gene copy numbers between the samples tested
[27]. Here, RNase P which known to exist in two copies in
a diploid genome is recommended as the standard refer-
ence assay for copy number quantitation experiments. This
assay detects the RNase P RNA component H1 (H1RNA)
gene (RPPH1) on chromosome 14, cytoband 14q11.2.
The PCR products were quantified in triplicate, and the
standard deviation (SD) and coefficient of variation (CV)
were calculated based on 3 runs. To control for reaction
quality, each reaction plate also included a calibrator, a
positive control, and a no-template control (NTC). Data
from a plate were included if the calibrator CV was less
than 5%, the positive control CV and sample CVs were all
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across-plate data, the CVs of the positive control had to be
similar and the NTC had to be negative.
Data analyses
Significance of the differences between the distributions
of TSHR and TLR7 CNV in groups (healthy controls,
GD and GO) was estimated by Chi square test or Fisher
exact test. Odds ratios (OR) and 95% confidence inter-
vals (CI) were estimated by logistic regression models.
Age and gender were adjusted in multivariate models.
Because the TLR7 gene located on chromosome X, the
interaction between gender and CNV of the TLR7 gene
was investigated. If the interaction term was not signifi-
cant, males and females would be combined to further
analyses. To estimate OR, the reference category was
normal CNV which are CNV = 2 for TSHR gene, CNV = 2
for TLR7 gene in females and CNV = 1 for TLR7 gene in
males. Based on the reference category, the risk of GD/
GO associated with the absolute TSHR/TLR7 CNV was
estimated by comparing cases and controls groups by
CNV less than normal CNV and CNV more than normal
CNV.
Results
In present study, the TSHR and TLR7 genes showed
variation in CN in a Chinese population in Taiwan. Spe-
cifically, 14.6% and 3.5% of this population had abnormal
CNV for TSHR and TLR7, respectively.
The distribution of TSHR copy number variation
The distribution of TSHR CNV in GD or GO patients is
summarized in Table 1. There was association between
TSHR CNV and GD (p value for Fisher’s exact test was
0.01). However, the distributions of TSHR CNV in the
GO patients and healthy controls were not significantly
different (p value for Fisher’s exact test was 0.06). In
univariate analyses, a harmful effect of abnormal TSHR
CNV (CNV <2) on the development of GD and GO were
observed (OR = 2.63; 95% CI = 1.31-5.25 and OR = 2.35;Table 1 The distribution of TSHR copy number variation in he
Graves’ ophthalmology
Healthy control (N = 196) GD (N = 481) GO (N = 203)
CNV N (%) N (%) N (%)
< 2 10 (5.1) 59 (12.3) 23 (11.3)
2 178 (90.8) 400 (83.2) 174 (85.7)
>2 8 (4.1) 22 (4.6) 6 (3.0)
P valuea 0.01* 0.06
GD, Graves’ disease. GO, Graves’ ophthalmology. CNV, copy number variance. N = n
aP value was calculated by Fisher’s exact test. Statistically significant results are indi
bUnivariate analyses. Statistically significant results are indicated by asterisk (*).
cMutivariates analyses, adjusted for age and gender, interaction term (gender*TSHR95% CI = 1.09-5.09 for comparing healthy control with
GD and GO, respectively). After adjusting for age and
gender, the results remain significant.
The distribution of TLR7 copy number variation
The distribution of TLR7 CNV of healthy control sub-
jects and GD patients is shown in Table 2. In healthy
control subjects, 94.9% of healthy control and 97.1% of
GD patients had normal TLR7 CNV. The association be-
tween healthy control and GD or GO were not observed
(p values for Fisher’s exact test were 0.13 and 0.09, re-
spectively). When we adjusted age and gender in the
multivariate logistic regression model, a protective effect
of lower than normal CNV for TLR7 (CNV < 2 for fe-
male and CNV < 1 for male), on development of GD was
observed (OR = 0.24; 95% CI = 0.07-0.75). All of GD sub-
jects with CNV less than normal CNV were females (n = 6).
The interaction term between gender and CNV of the
TLR7 gene was investigated and the result was not signifi-
cant (p value > 0.05).
Discussion
In the present study, variation in the CNs of TSHR and
TLR7 gene was observed in the Chinese population in
Taiwan, and the effects of this CNV on GD and GO
were investigated. To the best of our knowledge, this is
the first study to show that CNV in TSHR and TLR7 is
associated with GD/GO in the Chinese population in
Taiwan. Previous studies on the effects of single nucleo-
tide polymorphisms of the TSHR gene on GD have
yielded inconsistent results [14,16,28]. Small study sam-
ple size and studying difference population for genetic
diversity may be the reasons for these non-significant or
inconsistent finding. But, a statistically significant associ-
ation between CNV of the TSHR gene and GD/GO was
identified in present study. Genetic variation within the
TSHR region may influence TSHR structure, expression
and/or post-translational processing, which in turn could
initiate or exacerbate the autoimmune response against
the TSHR in GD [29].althy control and patients with Graves’ disease and
GD versus Healthy control GO versus Healthy control
OR (95% CI)b OR (95% CI)c OR (95% CI)b OR (95% CI)c
2.63(1.31-5.25)* 2.61 (1.29-5.28)* 2.35 (1.09-5.09)* 2.54 (1.15-5.61)*
1 1 1 1
1.22 (0.54-2.80) 1.34 (0.55-3.27) 0.77 (0.26-2.26) 0.98 (0.32-3.01)
umber. OR, odds ratio. CI, confidence interval.
cated by asterisk (*).
) was not significant. Statistically significant results are indicated by asterisk (*).
Table 2 The distribution of TLR7 copy number variation in healthy control and patients with Graves’ disease and
Graves’ ophthalmology
Healthy control (N = 196) GD (N = 484) GO (N = 203) GD versus Healthy control GO versus Healthy control
CNV N (%) N (%) N (%) OR (95% CI)c OR (95% CI)d OR (95% CI)c OR (95% CI)d
CNV < normal CNV 7 (3.6) 6 (1.2) 1 (0.5) 0.34 (0.11-1.02) 0.24 (0.07-0.75)* 0.13(0.02-1.09) 0.13(0.02-1.05)
Normal CNVa 186 (94.9) 470 (97.1) 200 (98.5) 1 1 1 1
CNV > normal CNV 3 (1.5) 8 (1.7) 2 (1.0) 1.06 (0.28-4.02) 1.32 (0.33-5.26) 0.62 (0.10-3.75) 0.67 (0.11-4.15)
P valueb 0.13 0.09
GD, Graves’ disease. GO, Graves’ ophthalmology. CNV, copy number variation. N = number. OR, odds ratio. CI, confidence interval. #, number.
aCNV = 1 for male or CNV = 2 for female.
bP value was calculated by Fisher’s exact test.
cUnivariate analyses. Statistically significant results are indicated by asterisk (*).
dMutivariates analyses, adjusted for age and gender, interaction term (gender*TLR7) was not significant. Statistically significant results are indicated by asterisk (*).
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receptors that recognize nuclear material from apoptotic
debris. Researchers have demonstrated that TLR7 plays an
important role in producing IFN-α, which is a critical
player in the innate and adaptive immune system [30,31].
Therefore, it is possible that CNV in TLR7 gene could
modulate the autoimmune response to nuclear material
[12]. Our results showed that TLR7 CNV is associated
with genetic susceptibility to GD, with a wide confidence
interval. The issue of limited study power due to the small
effect size and limited sample size should be noted. More-
over, a link between TLR7 gene dosage and increased
autoimmunity has been identified in a mouse model of
systemic lupus erythematosus (SLE) [32,33]; however, the
effects of varying TLR7 CN on SLE were inconsistent
[10,12,33]. In the present study, a protective effect of
lower than normal TLR7 CNV (CNV = 1 for female)
and a harmful effect of higher than normal CNV (result
was not significant) on the development of GD was ob-
served. However, a dosage effect of TLR7 on GD/GO
was not observed (data not shown). The relationship
betweeen TLR7 CNV, TLR7 expression, and IFN-α acti-
vation will need to be investigated in future studies.
In our study, the effects of TLR7 CNV on GD and GO
were greater when the analyses were limited to female
subjects. This gender-related difference in TLR7 function
has been observed previously. For example, Berghofer
et al. (2006) showed that female SLE patients produce
significantly more IFN-α after TLR7 stimulation than
male SLE patients. Epidemiological studies also indicate
that GD predominantly affects women [34]. Many stud-
ies have confirmed that elevated levels of IFN-α play a
key role in the development of clinical and experimental
GD [35]. Therefore, TLR7 CNV may contribute to the
pathogenesis of GD in female patients through a gender-
dependent immune response. However, the effect of
TLR7 CNV in male subjects is unclear owing to the
small number of male subjects in this study. Therefore, a
larger sample size, especially of the male population willbe needed in future studies to confirm the importance of
TLR7 CNV as a genetic marker of GD.
Conclusions
In conclusion, this study suggests that CNV in TSHR
and TLR7 is associated with the development of GD.
TSHR and TLR7 CNV might therefore be potential diag-
nostic tests or therapeutic targets for GD.
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